Huizenga Theodore Alan, an insider at Ultragenyx Pharmaceutical Inc (RARE), sold 50,450 shares of the company on December 28, 2025, at a price of $34.38 per share, totaling $1.73 million. Following this transaction, he retains an equal number of shares in the company.
Ultragenyx, headquartered in Novato, California, focuses on developing treatments for rare genetic diseases. The biopharmaceutical company’s pipeline includes therapies across biologics, small molecules, AAV gene therapy, and nucleic acid products. It has four approved products, including Crysvita for X-linked hypophosphatemia and Mepsevii for mucopolysaccharidosis VII.
The company has a market capitalization of $1.9 billion and reported a trailing twelve-month EPS of -5.94. Upcoming earnings are scheduled for May 4, 2026, with an estimated EPS of -1.64 and revenue of $175.8 million.
Insider transactions, such as this sale, are reported to the SEC, providing transparency regarding executive actions. While such moves can indicate personal financial strategies, they should be considered alongside broader market factors and patterns of insider activity.